Key positives include a strong cash position and projected runway into the second half of 2027, a clearly differentiated TCR discovery and development platform, and a focused clinical strategy in hematologic malignancies supported by encouraging early data. The Amgen collaboration in autoimmune disease provides third‑party validation and diversification, while disciplined non‑R&D spending helps ensure that most resources are directed toward value‑creating science.

Major concerns center on the absence of revenue, persistent and substantial cash burn, and a large accumulated deficit, all of which make the company dependent on successful clinical outcomes and ongoing access to external capital. Clinical and regulatory risks are significant in complex cell therapies, competition is intense from larger and better‑resourced players, and any delay or disappointment in trial results could accelerate financing pressure and potential shareholder dilution.

Over the next few years, TScan’s trajectory will be shaped by data readouts from the ALLOHA trial and the progression of TSC‑101 into a pivotal study, the early clinical experience with TSC‑102, and visible progress in its autoimmune collaboration and in vivo TCR efforts. With meaningful cash on hand, the company has time to pursue these milestones, but until there is clear clinical validation and a path to commercialization or substantial partnerships, TScan remains a development‑stage story with outcomes that are highly uncertain and sensitive to binary clinical events.